Lucid Diagnostics Inc. (LUCD) company profile
Close on Nov 17, 2026Market cap $81.09MP/E –Yield –
About Lucid Diagnostics
Surgical & Medical Instruments & Apparatus, SIC 3841
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on preventing esophageal adenocarcinoma in patients with gastroesophageal reflux disease. Its core products include EsoCheck, a noninvasive swallowable balloon capsule catheter used for targeted esophageal cell sampling, and EsoGuard, a targeted next-generation sequencing DNA test designed to detect esophageal precancer. The company markets its diagnostic products to primary care and gastroenterology physicians, self-insured employers, unions, and healthcare systems, while also providing testing through commercial health network arrangements and a direct-to-consumer telemedicine program.
The company operates its own clinical laboratory in Lake Forest, California, along with dedicated physical Lucid Test Centers and satellite collection sites in physician offices. EsoCheck has received regulatory clearance in the United States and CE Mark certification in Europe, and cell collection devices are produced through third-party manufacturing partners. The text does not disclose the location of the corporate headquarters.
Summary of the business section of Lucid Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lucid Diagnostics Inc.
- Founded
- 2018
- Headquarters
- New York, NY
- Address
- 360 Madison Avenue, 25th Floor 10017
- Phone
- (212) 949-4319
- Website
- luciddx.com
- Employees
- 82, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- LUCD
- Exchange
- Nasdaq
- IPO date
- Oct 15, 2021
- Shares outstanding
- 203M, Aug 10, 2026
- Public float
- $82.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1799011
- CUSIP
- 54948X109
- ISIN
- US54948X1090
- FIGI
- BBG012NYMLC0
- Share class FIGI
- BBG012NYMM65
- EIN
- 82-5488042
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lishan Aklog | Chief Executive Officer, Director | 3,636,627 |
| Victoria Tou-ho Lee | Chief Medical Officer | 650,000 |
| Dennis M. McGrath | Chief Financial Officer | 1,813,569 |
| Shaun O'Neil | President and COO | 1,446,763 |
| Michael Adam Gordon | General Counsel and Secretary | 1,000,000 |
| Dennis Matheis | Director | 1,033,443 |
| Debra White | Director | 235,800 |
| James L. Cox | Director | 405,120 |
| Ronald M. Sparks | Director | 320,460 |
| John R. Palumbo | Director | 338,000 |
| Stanley Lapidus | Director | 337,392 |
| Jacque J. Sokolov | Director | 320,460 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Lishan Aklog Chairman of the Board and Chief Executive Officer | $300.00K | $150.00K | $447.00K | $897.00K | +26% |
| Dennis M. McGrath Chief Financial Officer | $225.00K | $78.75K | $447.00K | $750.75K | +18% |
| Shaun M. O’Neil President and Chief Operating Officer | $300.00K | $75.00K | $447.00K | $822.00K | +15% |
| Michael A. Gordon General Counsel and Corporate Secretary | $250.00K | $62.50K | $447.00K | $759.50K | +15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 15, 2021
- Offer price
- $14.00
- Securities offered
- 5,000,000
- Gross proceeds
- $70.00M
- Exchange
- Nasdaq
- First trading day
- Oct 14, 2021
- First-day close
- $11.76-16.0%
- Lock-up ends (est.)
- Apr 12, 2022
“Per Share Total Public offering price $ 14.00 $ 70,000,000 Underwriting discount (1) $ 0.98 $ 4,900,000 Proceeds to us, before offering expenses $ 13.02 $ 65,100,000 (1) See “Underwriting” beginning on page 146 of this prospectus for a description of the compensation payable to, and other arrangements with, the und”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 23, 2026 we have 82 employees (all of whom are full-time employees), inclusive of our executive officers – our Chairman of the Board of Directors and Chief Executive Officer (“CEO”), our President and Chief Operating Officer (“President” or “COO”), our Chief Financial Officer (“CFO”), our General Counsel and Secretary (“General”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 16, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 25, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 21, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 28, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 24, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 1, 2022 | Late filing | Notification of late filing |
| Mar 3, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 15, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 12, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?